|
Percentage of patients group achieving various levels of pain relief at 6 weeks compared with baseline |
|||||
| Percentage reduction in pain from baseline |
Treatment group: etoricoxib daily dose (mg) |
||||
|
|
|||||
| 0 (placebo) (n = 57) |
5 (n = 114) |
10 (n = 105) |
30 (n = 102) |
60 (n = 109) |
|
|
|
|||||
| >0 |
61 |
77 |
79 |
84 |
88 |
| ≥ 10 |
46 |
67 |
69 |
75 |
83 |
| ≥ 20 |
30 |
55 |
57 |
58 |
74 |
| ≥ 30 |
25 |
44 |
42 |
50 |
66 |
| ≥ 40 |
19 |
32 |
31 |
43 |
55 |
| ≥ 50 |
11 |
19 |
25 |
34 |
49 |
| ≥ 60 |
9 |
11 |
15 |
27 |
35 |
| ≥ 70 |
2 |
6 |
11 |
17 |
29 |
| ≥ 80 |
2 |
4 |
5 |
5 |
19 |
| ≥ 90 |
0 |
1 |
3 |
1 |
5 |
Moore et al. Arthritis Research & Therapy 2008 10:R39 doi:10.1186/ar2394 |
|||||